zepbound glp-1 receptor agonist hydration effects 2025 Your guide to side 11 GLP-1 Side Effects You

S., Fussman, C., & Imes, G

But these medications have different approved uses

This legislation, if passed, would require Medicare to cover obesity medications, which could open the door for broader insurance coverage

Moreover, semaglutide2 is going generic in Canada, India and China in 2026, so brace for international adoption and black market export rings

Other companies are exploring quadruple agonists that add amylin receptor activation to the mix

Inflation Reduction Act (effective 2027) may improve affordabilityparticularly for Medicare recipientscurrent dynamics underscore the complex interplay of clinical promise, economic burden, and political ideology .The rapid growth of GLP-1 prescribing marks a new chapter in the treatment of obesity